Premutation Females with preFXTAS
Authors:
- Valentina LianiVLValentina Liani
- Carme TorrentsCTCarme Torrents
- Elisa RolleriERElisa Rolleri
- Nor Azyati YusoffNYNor Azyati Yusoff
- Narueporn LikhitweerawongNLNarueporn Likhitweerawong
- Sydney MooreSMSydney Moore
- Flora TassoneFTFlora Tassone
- Andrea SchneiderASAndrea Schneider
- Ellery SantosESEllery Santos
- Hazel M. B. BiagHBHazel M. B. Biag
- James A. BourgeoisJBJames A. Bourgeois
- Kathryn E. UnruhKUKathryn E. Unruh
Open Access
- 20 March 2025
- journal article
- case report
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (6) , 2825
Abstract
Fragile-X-associated tremor/ataxia syndrome (FXTAS) is a progressive neurodegenerative disorder associated with the FMR1 gene premutation, characterized by the presence of 55 to 200 CGG triplet repeat expansions. Although the initial symptoms of FXTAS typically manifest in males around the age of 60 with motor symptoms and cognitive deficits, the presentation and progression in females differ. Women, in fact, exhibit a higher prevalence of neuropsychiatric symptoms, with an earlier onset compared to the motor symptoms observed in men. The following article reports on ten cases of women with a diagnosis of FMR1 gene premutation, originating from two medical centers. All the women in the study exhibited neuropsychiatric symptoms and subtle neurological signs as common features. Symptoms typically observed in the male population, such as tremors and cerebellar ataxia, were either absent or significantly reduced in the female cohort. Conversely, there was a higher prevalence of neuropsychiatric symptoms among the women. Neurocognitive impairment was only minimally evident, with mild executive dysfunction and memory complaints noted in a subset of cases. For this reason, we propose the terminology preFXTAS or prodromic FXTAS to define a clinical presentation in women characterized by early manifestations of FXTAS that do not entirely fulfill the established diagnostic criteria but exhibit MRI evidence of white matter alterations suggesting the initiation of the disease process. The study underscores the importance of establishing new diagnostic criteria for FXTAS and, at the same time, developing new biomarkers and interview checklists/assessment scales dedicated to females.Keywords
Funding Information
- NICHD (HD036071, NIH P50 HD 103526, NIH/NINDS R01 NS125737, NIH/NIA R21 080923)
- MIND Institute IDDRC (HD036071, NIH P50 HD 103526, NIH/NINDS R01 NS125737, NIH/NIA R21 080923)
This publication has 54 references indexed in Scilit:
- FXTAS Neuropathology Includes Widespread Reactive Astrogliosis and White Matter Specific Astrocyte DegenerationAnnals of Neurology, 2024
- The Corpus Callosum Splenium Sign in Fragile X‐Associated Tremor Ataxia SyndromeMovement Disorders Clinical Practice, 2016
- High functioning male with fragile X syndrome and fragile X‐associated tremor/ataxia syndromeAmerican Journal of Medical Genetics Part A, 2015
- Immune‐mediated disorders among women carriers of fragile X premutation allelesAmerican Journal of Medical Genetics Part A, 2012
- Depression and anxiety symptoms among women who carry the FMR1 premutation: Impact of raising a child with fragile X syndrome is moderated by CRHR1 polymorphismsAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012
- Sleep apnea in fragile X premutation carriers with and without FXTASAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011
- Co‐occurring conditions associated with FMR1 gene variations: Findings from a national parent surveyAmerican Journal of Medical Genetics Part A, 2008
- Expanded clinical phenotype of women with the FMR1 premutationAmerican Journal of Medical Genetics Part A, 2008
- Penetrance of the Fragile X–Associated Tremor/Ataxia Syndrome in a Premutation Carrier PopulationJAMA, 2004
- FMRP expression as a potential prognostic indicator in fragile X syndromeAmerican Journal of Medical Genetics, 1999